Feasibility of omega-3 fatty acid supplementation as an adjunct therapy for people with chronic obstructive pulmonary disease: study protocol for a randomized controlled trial
There is evidence to support the use of supplementation with long-chain omega-3 polyunsaturated fatty acids (LCn-3PUFA) from oily fish or fish oil for the treatment of various inflammatory diseases such as rheumatoid arthritis. Chronic obstructive pulmonary disease (COPD) is a progressive, terminal disease characterized by persistent airflow limitation, lung and systemic inflammation. To date, one randomized controlled trial has been published that assessed the efficacy of LCn-3PUFA in people with this condition. The aim of this article is to discuss the feasibility of conducting a trial to evaluate fish oil supplementation as adjunct therapy in people with COPD.
A 16-week parallel, double-blind, randomized, placebo-controlled dietary supplementation trial will be evaluated. Forty participants meeting spirometric and clinical criteria for COPD will be recruited from metropolitan Adelaide, South Australia. Participants will be randomized by minimization, based on a score derived from the modified Medical Research Council Scale for breathlessness, to receive 6 g/day of fish oil (approximately 3.6 g/day of LCn-3PUFA), or placebo (6 g/day of corn oil) capsules. Feasibility outcomes (recruitment, retention, supplement adherence, and time lost to exacerbation) and scientific outcomes (effect size and estimates of variance for inflammatory biomarkers, incorporation of LCn-3PUFA into erythrocytes, small airways function, dyspnea and functional exercise capacity) will be assessed pre- and post-intervention. Key feasibility criteria include recruitment of 40 participants in 52 weeks, 75% participant retention rate, 2% increase in the proportion of long-chain omega-3 fatty acids in erythrocytes, and a positive moderate effect size in at least three efficacy measures.
There are a number of challenges in designing supplementation intervention studies with this population. These include the lack of prior data from which to select appropriate primary outcomes or to estimate effect sizes, and the feasibility of continuous supplementation in a population characterized by multiple comorbidities and a high likelihood of exacerbations, potentially requiring hospitalization or change in medication. Upon completion of this protocol, feasibility outcomes will guide the direction of future multicentre dietary interventions in this population.
Australia and New Zealand Clinical Trials Register (ANZCTR): ACTRN12612000158864
- Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. [http://www.goldcopd.org/]
- The top 10 leading causes of death by broad income group. [http://www.who.int/mediacentre/factsheets/fs310/en/index.html]
- World Health Organisation: World Health Statistics. Geneva; 2008.
- Parshall MB, Schwartzstein RM, Adams L, Banzett RB, Manning HL, Bourbeau J, Calverley PM, Gift AG, Harver A, Lareau SC, Mahler DA, Meek PM, O'Donnell DE: An official American Thoracic Society Statement: Update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med 2012, 185:435–452. CrossRef
- Halpin DM: Systemic effects of chronic obstructive pulmonary disease. Expert Rev Respir Med 2007, 1:75–84. CrossRef
- Barnes PJ, Celli BR: Systemic manifestations and comorbidities of COPD. Eur Respir J 2009, 33:1165–1185. CrossRef
- Gan WQ, Man SFP, Senthilselvan A, Sin DD: Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and meta-analysis. Thorax 2004, 59:574–580. CrossRef
- Oudijk EJ, Lammers JW, Koenderman L: Systemic inflammation in chronic obstructive pulmonary disease. Eur Respir J Suppl 2003, 46:5s-13s. CrossRef
- Harris KA, Hill AM, Kris-Etherton PM: Health benefits of marine-derived omega-3 fatty acids. ACSMS Health Fit J 2010, 14:22.
- Calder PC: Mechanisms of action of (n-3) fatty acids1,2. J Nutr 2012, 142:592S-599S. CrossRef
- Healy D, Wallace F, Miles E, Calder P, Newsholme P: Effect of low-to-moderate amounts of dietary fish oil on neutrophil lipid composition and function. Lipids 2000, 35:763–768. CrossRef
- Barnes PJ, Karin M: Nuclear Factor-kB- A pivotal transcription factor in chronic inflammatory diseases. New Engl J Med 1997, 336:1066–1071. CrossRef
- Matsuyama W, Mitsuyama H, Watanabe M, Oonakahara K-i, Higashimoto I, Osame M, Arimura K: Effects of omega-3 polyunsaturated fatty acids in inflammatory markers in COPD. CHEST 2005, 128:3817–3827. CrossRef
- Broekhuizen R, Wouters E, Creutzberg E, Weling-Scheepers C, Schols A: Polyunsaturated fatty acids improve exercise capacity in chronic obstructive pulmonary disease. Thorax 2005, 60:376–382. CrossRef
- de Batlle J, Sauleda J, Balcells E, Gomez F, Mendez M, Rodriguez E, Barreiro E, Ferrer JJ, Romieu I, Gea J, Anto JM, Garcia-Aymerich J: Association between omega-3 and omega-6 fatty acid intakes and serum inflammatory markers in COPD. J Nutr Biochem 2012, 23:817–821. CrossRef
- Hirayama F, Lee AH, Binns CW, Hiramatsu N, Mori M, Nishimura K: Dietary intake of isoflavones and polyunsaturated fatty acids assocaited with lung function, breathlessness and the prevalence of chronic obstructive pulmonary diesease: Possible protective effect of traditional Japanese diet. Mol Nutr Food Res 2010, 54:909–917. CrossRef
- McKeever TM, Lewis SA, Cassano PA, Ocke M, Burney P, Britton J, Smit HA: The relation between dietary intake of individual fatty acids, FEV1 and respiratory disease in Dutch adults. Thorax 2008, 63:208–214. CrossRef
- Shahar E, Boland LL, Folsom AR, Tockman M, McGovern PG, Eckfeldt JH: Docosahexaenoic Acid and smoking-related chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999, 159:1780–1785. CrossRef
- A new view of statistics: A scale of magnitudes for effect statistics. [http://www.sportsci.org/resource/stats/]
- Barr GR: The Chronic Obstructive Pulmonary Disease Fish Oil Pilot Trial (COD-Fish). Clinical Trials.gov.; 2008. http://clinicaltrials.gov/ct2/show/NCT00835289?term=fish+oil+AND+COPD&rank=3
- Engelen M: Eicosapentaenoic Acid and Protein Modulation to induce Anabolism in Chronic Obstructive Pulmonary Disease (COPD): Aim 2. Clinical Trials.gov.; 2012. http://clinicaltrials.gov/ct2/show/NCT01624792?term=eicosapentaenoic+acid+and+protein+modulation&rank=1
- Fuld J, Kilduff L, Neder J, Pitsiladis Y, Lean M, Ward S, Cotton M: Creatine supplementation during pulmonary rehabilitation in chronic obstructive pulmonary disease. Thorax 2005, 60:531–537. CrossRef
- Lehouck A, Mathieu C, Carremans C, Baeke F, Verhaegen J, Van Eldere J, Decallonne B, Bouillon R, Decramer M, Janssens W: High doses of vitamin D to reduce exacerbations in chronic obstructive pulmonary disease. Ann Intern Med 2012, 156:105–114. CrossRef
- Steiner M, Barton R, Singh S, Morgan M: Nutritional enhancement of exercise performance in chronic obstructive pulmonary disease: a randomised controlled trial. Thorax 2003, 58:745–751. CrossRef
- Arain M, Campbell MJ, Cooper CL, Lancaster GA: What is a pilot or feasibility study? A review of current practice and editorial policy. BMC Med Res Methodol 2010, 10:1–7. CrossRef
- Thabane L, Ma J, Chu R, Cheng J, Ismaila A, Rios LP, Robson R, Thabane M, Giangregorio L, Goldsmith CH: A tutorial on pilot studies: the what, why and how. BMC Med Res Methodol 2010, 10:1–10. CrossRef
- van Teijlingen ER, Rennie A-M, Hundley V, Graham W: The importance of conducting and reporting pilot studies: the example of the Scottish Births Survey. J Adv Nurs 2001, 34:289–295. CrossRef
- Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Lochs H, Mantovani G, Marks D, Mitch WE, Muscaritoli M, Najand A, Ponikowski P, Rossi Fanelli F, Schambelan M, Schols A, Schuster M, Thomas D, Wolfe R, Anker SD: Cachexia: a new definition. J Clin Nutr 2008, 27:793–799. CrossRef
- Feasibility and Pilot studies. [http://www.netscc.ac.uk/glossary/#glos6]
- Browne RH: On the use of a pilot sample for sample size determination. Stat Med 1995, 14:1933–1940. CrossRef
- Lancaster GA, Dodd S, Williamson PR: Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract 2004, 10:307–312. CrossRef
- Altman DG, Bland MJ: Treatment allocation by minimisation. Brit Med J 2005, 330:843. CrossRef
- Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975, 31:103–115. CrossRef
- Dietary guidelines for Australian adults. [http://www.nhmrc.gov.au/guidelines/publications/n29-n30-n31-n32-n33-n34]
- Skulas-Ray AC, Kris-Etherton PM, Harris WS, Vanden Heuvel JP, Wagner PR, West SG: Dose–response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia. Am J Clin Nutr 2011, 93:243–252. CrossRef
- Su K-P, Huang S-Y, Chiu C-C, Shen WW: Omega-3 fatty acids in major depressive disorder: A preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharm 2003, 13:267–271. CrossRef
- Giles GG, Ireland PD: Dietary questionnaire for epidemiological studies (version 2). Melbourne: The Cancer Council Victoria; 1996.
- Xinying PX, Noakes M, Keogh J: Can a food frequency questionnaire be used to capture dietary intake data in a 4 week clinical intervention trial? Asia Pac J Clin Nutr 2004, 13:318–323.
- Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987, 40:373–383. CrossRef
- Fishman PA, Goodman MJ, Hornbrook MC, Meenan RT, Bachman DJ, Rosetti MCOK: Risk adjustment using automated ambulatory pharmacy data: the RxRisk model. Med Care 2003, 41:84–99. CrossRef
- Milte CM, Coates AM, Buckley JD, Hill AM, Howe PRC: Dose-dependent effects of docosahexaenoic acid-rich fish oil on erythrocyte docosahexaenoic acid and blood lipid levels. Brit J Nutr 2008, 99:1083–1088. CrossRef
- Effing TW, Kerstjens HAM, van der Valk PDLPM, Zielhuis GA, van der Palen J: The (cost)-effectiveness of self-treatment of exacerbations on the severity of exacerbations in COPD patients: the COPE-II study. Thorax 2009, 64:956–962. CrossRef
- Bligh EG, Dyer WJ: A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959, 37:911–917. CrossRef
- Folch J, Lees M, Sloane Stanley GH: A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957, 226:497–509.
- Lepage G, Roy CC: Direct transesterfication of all classes of lipids in a one-step reaction. J Lipid Res 1986, 27:114–120.
- Milte CM, Parletta N, Buckley JD, Coates AM, Young RM, Howe PRC: Eicosapentaenoic and docosahexaenoic acids, cognition, and behaviour in children with attention-deficit/hyperactivity disorder: A randomized controlled trial. Nutrition 2012, 28:670–677. CrossRef
- Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CPM, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pederson OF, Pellegrino R, Viegi G, Wanger J: Standardisation of spirometry. Eur Respir Journal 2005, 26:319–338. CrossRef
- Dubois AB, Brody AW, Lewis DH, Burgess BF Jr: Oscillation mechanics of lungs and chest in man. J Appl Phys 1956, 8:587–594.
- MacIntyre N, Crapo R, Viegi G, Johnson DC, van der Grinten CPM, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, Gustafsson P, Hankinson J, Jensen R, McKay R, Miller MR, Navajas D, Pederson OF, Pellegrino R, Wanger J: Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005, 26:720–735. CrossRef
- Wanger J, CJ L, Coates A, Pederson OF, Brusasco V, Burgos F, Casaburi R, Crapo R, Enright P, van der Grinten CPM, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pellegrino R, Viegi G: Standardisation of the measurement of lung volumes. Eur Respir J 2005, 26:511–522. CrossRef
- Mahler DA, Ward J, Waterman LA, McCusker C, ZuWallack R, Baird JC: Patient-reported dyspnea in COPD reliability and association with stage of disease. CHEST 2009, 136:1473–1479. CrossRef
- Mahler D, Wells CK: Evaluation of clinical methods for rating dyspnea. CHEST 1988, 93:580–586. CrossRef
- American Thoracic Society: ATS Statement:Guidelines for the six-minute walk test. Am J Crit Care 2002, 166:111–117. CrossRef
- Hernandes N, Wouters EFM, Meijer K, Annegarn J, Pitta F, Spruit MA: Reproducibility of 6-minute walking test in patients with COPD. Eur Respir J 2011, 38:261–267. CrossRef
- Goldstein RSGEH: Randomised controlled trial of respiratory rehabilitation. Lancet 1994, 344:1394. CrossRef
- Puhan M, Behnke M, Frey M, Grueter T, Brandli O, Lichtenschopf A, Guyatt G, Schunemann H: Self-administration and interviewer-administration of the German Chronic Respiratory Questionnaire: instrument development and assessment of validity and reliability in two randomised studies. Health Qual Life Outcomes 2004, 2:1. CrossRef
- Enfield K, Gammon S, Floyd J, Falt C, Patrie J, Platts-Mills TA, Truwit J, Shim MY: Six-minute walk distance in patients with severe end-stage COPD: Association with survival after inpatient pulmonary rehabilitation. J Cardiopulm Rehabil 2011, 30:195–202.
- Beatty AL, Schiller NB, Whooley MA: Six-minute walk test as a prognostic tool in stable coronary heart disease: data from the heart and soul study. Six-minute walk test as a prognostic Tool in CHD. Arch intern Med 2012, 18:1–7.
- Spinhoven PH: A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjects. Psychol Med 1997, 27:363–370. CrossRef
- Zigmond AS, Snaith R: The hospital anxiety and depression scale. Acta Psychiat Scand 1983, 67:361–370. CrossRef
- Ng T: Depressive symptoms and COPD: Effect on mortality, hospital readmission, symptom burden, functional status and quality of life. Arch intern Med 2007, 167:60–67. CrossRef
- Williams J, Singh S, Sewell L, Guyatt G, Morgan M: Development of a self-reported Chronic Respiratory Questionnaire (CRQ-SR). Thorax 2001, 56:954–959. CrossRef
- Schünemann H, Goldstein R, Mador M, McKim D, Stahl E, Puhan M, Griffith L, Grant B, Austin P, Collins R: A randomised trial to evaluate the self-administered standardised chronic respiratory questionnaire. Eur Respir J 2005, 25:31–40. CrossRef
- Spurzem JR, Rennard SI: Pathogenesis of COPD. Semin Respir Crit Care Med 2005, 26:142–153. CrossRef
- Delgado-Lista J, Perez-Martinez P, Lopez-Mirando J, Perez-Jimenez F: Long chain omega-3 fatty acids and cardiovascular disease: a systematic review. Brit J Nutr 2012, 107:s201-s213. CrossRef
- Miles E, Calder PC: Influence of marine n-3 polyunsaturated fatty acids on immune function and systematic review of their effects on clinical outcomes in rheumatoid arthrtis. Brit J Nutr 2012, 107:S171-S184. CrossRef
- Calder PC: Omega-3 polyunsaturated fatty acids and inflammatory processes: Nutrition or pharmacology? Br J Clin Pharmacol 2012, 75:645–662.
- Lacasse Y, Goldstein RS, Lasserson J, Martin S: Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006., 18: CD003793
- Feasibility of omega-3 fatty acid supplementation as an adjunct therapy for people with chronic obstructive pulmonary disease: study protocol for a randomized controlled trial
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
- Online Date
- April 2013
- Online ISSN
- BioMed Central
- Additional Links
- Author Affiliations
- 43. Nutritional Physiology Research Centre, Sansom Institute for Health Research, School of Health Sciences, University of South Australia, City East Campus, Frome Road, Adelaide, South Australia, 5000, Australia
- 46. School of Population Health, University of South Australia, City East Campus, Frome Road, Adelaide, South Australia, 5000, Australia
- 44. Clinical Nutrition Research Centre, School of Biomedical Sciences & Pharmacy, University of Newcastle, University Drive, Callaghan, New South Wales, 2308, Australia
- 45. Faculty of Health Sciences, Repatriation General Hospital, Respiratory Medicine, Flinders University, Daws Road, Daw Park, Kragujevac, South Australia, 5041, Australia